### CARDIOVASCULAR TISSUE ENGINEERING IN PRECISION AND REGENERATIVE MEDICINE

Francesco S. Pasqualini, PhD

Associate Professor, Industrial Bioengineering, University of Pavia

Formerly: Harvard Wyss Institute in Boston Wyss translational center in Zurich **Contacts:** 

Email: francesco.pasqualini@unipv.it

Tel: (+39)351 611 3144

Twitter: @fspasqualini

LinkedIn: https://www.linkedin.com/in/fsp81






dall'Unione europea NextGenerationEU





# From synthetic biology, to tissue engineering, to synthetic matrix biology



Parker lab funding

DARPA DEFENSE ADVANCED RESEARCH PROJECTS AGENCY



National Center for Advancing Translational Sciences Pasqualini lab funding




# My original quest: What does it take to make cardiac tissue engineered products?

#### Roadmap (from 2010):

- Organ replacement: 20 years, >20B cells, different cell types
- Regenerative medicines: 10 years, >100Ms cells,
- Drug discovery: 5 years, <1M cells, single/multiple cell types


#### Roadblocks:

- Cells as building blocks
- High-quantity
- High-quality



- 1. Background: Organ-chips in precision and regenerative medicine
- 2. My work with the heart-chip in Boston
- 3. My work with regenerative cardiovascular prostheses in Zurich
- 4. My work in Synthetic Matrix Biology in Pavia
- 5. Discussion

# **Organs-on-chips (OOC)** are fail-fast/cheap platforms for predictive pre-clinical investigations



#### **Eroom law**

• The cost of getting a drug to the market has doubled yearly over the last 30 yrs



Pharma drug development cycle

Phase I

Phase II

Phase III

FDA review

Phase IV

Strategic decision

on target indication

5000–10 000 compounds

250 compounds

5 compounds

cohort: 20-10

Cohort

100-500

Cohort

1000-

5000

1 FDA

approved

drug

3

5

6.5

9

13

15

Compound success rates for clinical trials

~10%

compounds entering

stage advance to

the clinical

FDA-approval

of

trial

~40% of compounds advance

~1/3 of compounds advance

~2/3 of compounds advance

from Phase III to FDA approval

rom Phase II to Phase III

from Phase I to Phase II

% of total

R&D investment

er one new drug (US\$ 1.5-2B)

30%

Preclinical phase

50%

40%

60%


20%

Manufacturing


• Failures in the clinical trial phase are ethical and economical catastrophes

#### OOC are assays meant to fail candidate compounds pre-clinically

# Organs-on-chips (OOC) are fail-fast/cheap platforms for predictive pre-clinical investigations



# The Wyss/Emulate approach: General-purpose OOCs for safety, efficacy, and everything in between



The Harvard Wyss Institute OOC

- Human cell types + biomimetic stretch
- ~50 M\$ in DARPA/NIH funding

Overview 🛛			[
Total Funding Amount \$9		CB Rank (Company)	3,248
	te s a private company focused on commercializing lassachusetts, United States	Organs-on-Chips.	
Categories	Biotechnology, Health Care, Medical		
Headquarters Regions	Greater Boston Area, East Coast, New England		
ounded Date	2013		
ounders	Daniel Levner, Geraldine A. Hamilton, James Coon		
Operating Status	Active		
Funding Status	Late Stage Venture		
ast Funding Type	Series C		
Number of Employees	51-100		
.egal Name	Emulate, Inc.		
PO Status	Private		
Website	emulatebio.com		
acebook	View on Facebook		
inkedIn	View on LinkedIn		
witter	View on Twitter		
Phone Number	508-843-5324		

Emulate, Inc. is a private company focused on commercializing Organs-on-Chips as an automated human bioemulation platform that achieves a new standard for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate is...

Read More

#### Emulate, Inc

- >100 M\$ in private investments
- Co-development deals with Pharma

Emulate, the dominant player in this market, doesn't have a heart chip

### Heart-chips powered by human pluripotent stem cellderived cardiomyocytes for disease modeling


#### **Cell sources**

- Patient-specific
- Genome-edited

#### Type of diseases

- Genetic disorders
- Single mutations

Key application in this space is the ability to model diseases




- 1. Background: Organ-chips in precision and regenerative medicine
- 2. My work with the heart-chip in Boston
- 3. My work with regenerative cardiovascular prostheses in Zurich
- 4. My work in Synthetic Matrix Biology in Pavia
- 5. Discussion

### Microfabrication Techniques to Recapitulate Cardiac Cell and Tissue Structure

### **Contractile structure in the heart:**


- Laminar tissues
- Aligned myofibrils
- Striated muscle cells

PA Ao Bos Ao Bos




 $\alpha$ -actinin,  $\beta$ -catenin, fibro

Scale: ~250 um




Scale: ~25 um






#### α-actinin, actin, chromatin



Scale: 10 um

Scale: ~10 cm

# Multiparametric assessment of cardiac tissue structure and function in the Heart-chip




### Functional signals in the heart:

- Action potential
- Calcium transient
- Contractile force

#### Heart-Chip Assay:


- Gene expression
- Electrochemical coupling
- Contractility

# Quantifying the structural maturation of hiPSC-CMs using a heart-chip platform



### *30% of hiPS-CM have mature contractile structure*


- Training dataset: Primary
  engineered tissues
- Test set: hiPS-CM
- Machine learning: Three independent classifiers




Scale: 25 um

#### $\alpha$ -actinin chromatin

### A heart-chip potency assay for cardiac cell therapy



### Heart-chip based disease-modeling



Park et al, Circ, 2019


#### Heart chip

- Optogenetics
- Muscular thin film
- Custom-made to have larger areas to study calcium propagation

#### Engineered WT and CVPT tissues


- 2.5D platform
- Laminar tissue architecture
- Well-developed contractile apparatus
- Electrically-competent tissues

# Tissue models from CPVT patient-derived hiPSC-CMs formed rotors under an exercise-mimicking stimulation protocol



### Healthy heart chip

Regular calcium waves w/out ISO




### **CPVT** heart chip

Reentry with exercise-like stimulation

- 1. Background: Organ-chips in precision and regenerative medicine
- 2. My work with the heart-on-a-chip in Boston
- 3. My work with regenerative cardiovascular prostheses in Zurich
- 4. My work in Synthetic Matrix Biology in Pavia
- 5. Discussion

### The extracellular matrix (ECM) in the heart




### Multiscale organization of the extracellular matrix (ECM):


- Fibrous, compact ECM maintain multi-chambered organ structure
- Anisotropic distribution of ECM proteins sustain laminar tissues
- ECM boundaries that physically constrained single cells

### **Biomimetic ECM cues to engineer native-like cardiac tissues**

### **Decellularized ECM** from tissue-engineered heart vessels is highly regenerative in a sheep model after one year.



# The regenerative decellularized ECM is a *complex mix of structural and functional proteins* (and even more with sugars)



Regenerative decellularized human ECM:


~6000 proteins

By gene ontology:

- ~60% of ECM proteins are structural.
- ~40% of ECM proteins are functional.

- 1. Background: Organ-chips in precision and regenerative medicine
- 2. My work with the heart-on-a-chip in Boston
- 3. My work with regenerative cardiovascular prostheses in Zurich
- 4. My work in Synthetic Matrix Biology in Pavia
- 5. Discussion


### What I used to believe: We could build a heart by sticking together high-quality cells



### I was wrong #1! Stem-cell-derived cardiac cells are fetal, so we should use them to grow hearts out, not build them.



Growing a heart



### I was wrong #2! If the ECM is just the glue that keeps the cells together, why is it so complex?!


### **Cells: functional blocks**

### **ECM:** structural glue




### **Decell.** human tissues proteomics:

40% of ECM proteins are functional.



### Synthetic Matrix Biology: Can use ECM parts to program tissues in the same way synthetic biologists use DNA parts to program cells?



Del Monte-Nieto, 2018\*

Scale: 500 µm

acid

Mouse heart tube: Myocytes on agrin, Endothelial cells on laminin, hyaluronic acid.

►Migration

### **Team:** A multidisciplinary, diverse group of people committed to understanding biology through engineering and *vice-versa*

#### **Senior scientists**



Moises di Sante

Molecular Biology



Alessandro Enrico

Materials science



**Julius Zimmermann** 

Modeling and simulation / Image analysis **PhD students** 

#### **Post-doctoral fellows**



Sandipan Chattaraj

Polymer physics



Saranya Vasudevan Molecular dynamics

### Agenda: New tools 1. New Cells

New Cells
 New Cells
 ECM-Cell interactions



**Bohdana Horda** 

Materials and manufacturing for bioengineering



#### Eloisa Torchia

Mechanobiology in engineered cell culture platforms



Melissa Pezzotti

Advanced optical methods in tissue engineering

FUCCIplex: A multiplexable cell cycle sensor for imaging-based phenotyping


### What do you need to make a cardiac tissue model? Cardiac (muscle) cells and their extracellular matrix (ECM)

### Contractile structure in the heart:

- Laminar tissues
- Aligned myofibrils
- Striated muscle cells

### **ECM Multiscale organization:**

- Multi-chambered organ
- Anisotropic 2D distribution
- Single-cell constraints




#### α-actinin, β-catenin, fibro

Scale: ~25 um


Scale: 10 um

### **FUCCIPIEX:** A cell cycle sensor that can be multiplexed with existing GFP/RFP-based sensors for cell structure/function




#### Sources: Pasqualini, JCB 2016 (top) and Koh et al, JCS 2017 (bottom)


### **FUCCIPIEX** is a good cell cycle sensor in HaCaT cells also expressing RFP-LifeAct




### Further multiplexing with GFP-based calcium sensors (Fluo-4) suggests cell cycle-dependent ATP-response


Raw data









Fluo-4 calcium sensitive dye



### **FUCCIplex in hiPSC and hiPSC-derived cardiomyocytes:** strategies for drug testing or regenerative medicine





### **CAG-FUCCIplex expression from human Rosa26 to** have a 4-color reporter line for all the tests



Actin, G1, S/G2/M Scale 25 um


### **Regenerative medicine:** hRosa26-CAG-FUCCIplex enables imaging of hiPSC-CM cell cycle re-entry with Agrin treatment






Actin, G1, S/G2/M Scale 100 and 25 um


### **Regenerative medicine:** We can look at calcium transients and sarcomere structures before and after cell cycle events



# HYDRA: HYdrogel Dispensing with Robotic Automation




### We develop HYDRA (HYdrogel Dispensing with Robotic Automation) to automate the fabrication of thin hydrogels in multi-well plates.




#### Working volumes in HT plates


#### **Meniscus effect in HT wells**




#### HYDRA method in a TC 96-well plate




### **Feasibility** – We characterized fish gelatin viscosity and stiffness by chemically crosslinking it with transglutaminase (TG)




## **Feasibility** – We characterized fish gelatin hydrogel thickness and flatness using confocal imaging.




## **Quantitative Phase Imaging compatibility** – We demonstrate HYDRA HTS plate can be used for imaging-based screening (drugs).



# **Scalability -** We move from a 96- to a 384-well plate scaling hydrogel volumes.




# **Scalability -** We move from a 96- to a 384-well plate scaling hydrogel volumes.



#### Automated fluorescence imaging of hydrogel w/ beads

#### Quality control single-gel analysis




# HYDRA 384-well plates can be used in advanced fluorescence microscopy applications.

## 18-hour HaCaT cell proliferation experiment

0 min

Nuclei in G1 phase Nuclei in S/G2 phase Actin

#### High-resolution confocal imaging




### Summary

1. HYDRA: High-throughput (really!!) engineered cell culture platforms to study ECM-cell interactions (pre-print out by the end of the month)

2. TEMPO: a suite of genetically encoded suite of fluorescent sensors for in hiPSCs (pre-print out by the end of the month)

But what about cell-ECM interactions?!

#### We can use FUCCIplex hiPSC to produce cardiac organoids or cardioids: in-vitro models of cardiac morphogenesis




hiPSC-derived cardiac organoid (live)


With Bertero's lab @ UniTO

Scale: 100 um


## We can further mine the dataset with the Matrisome database: by gene ontology ECM-associated genes participate in myocardial morphogenesis




## Interaction network analysis further supports an integrative role of the ECM in the biological processes linked with cardiac development.



# Agrin and laminin genes are differentially expressed across cell types



### Hyaluronic acid genes are differentially expressed across cell types



#### UMAP of Hyaluronic acid Genes Expression

### Thinking Outside the Cell: Let's make a Functionally Annotated ECM Atlas!

